In preclinical studies, B7-H4 blockade enhances T cell immune responses in bladder urothelial carcinoma patients and shows potential in combination with PD-L1 blockade in breast cancer, intensifying the anti-tumor immune response [137]. Here, VTCN1 is linked to neoplasm.